Vulvodynia: What We Know and Where We Should Be Going
Document Type
Article
Publication Date
4-2017
Abstract
Objective
The aim of the study was to review the current nomenclature and literature examining microbiome cytokine, genomic, proteomic, and glycomic molecular biomarkers in identifying markers related to the understanding of the pathophysiology and diagnosis of vulvodynia (VVD).
Materials and Methods
Computerized searches of MEDLINE and PubMed were conducted focused on terminology, classification, and “omics” variations of VVD. Specific MESH terms used were VVD, vestibulodynia, metagenomics, vaginal fungi, cytokines, gene, protein, inflammation, glycomic, proteomic, secretomic, and genomic from 2001 to 2016. Using combined VVD and vestibulodynia MESH terms, 7 references were identified related to vaginal fungi, 15 to cytokines, 18 to gene, 43 to protein, 38 to inflammation, and 2 to genomic. References from identified publications were manually searched and cross-referenced to identify additional relevant articles. A narrative synthesis of the articles was conducted; however, meta-analysis was not conducted because of substantial heterogeneity in the studies and limited numbers of control-matched studies.
Results
Varying definitions of VVD complicate a meta-analysis, and standard definitions will better allow for comparisons of studies and enhance the applicability of evidence to patient populations. Although data are still limited, genomic and molecular diagnostic testings continue to be investigated as potential tools for the diagnosis of VVD.
Repository Citation
Havemann, L. M.,
Cool, D. R.,
Gagneux, P.,
Markey, M. P.,
Yaklic, J. L.,
Maxwell, R.,
Iyer, A.,
& Lindheim, S.
(2017). Vulvodynia: What We Know and Where We Should Be Going. Journal of the Lower Genital Tract Disease, 21 (2), 150-156.
https://corescholar.libraries.wright.edu/obgyn/21
DOI
10.1097/LGT.0000000000000289
